Pancreatic Ductal Adenocarcinoma

Thus, conservative management with close surveillance may be feasible for carefully selected patients with small, asymptomatic tumors. However, additional cases are needed to clarify optimal management strategies.

This study reports AGP regimen as a promising therapeutic modality for PDAC, and provides a detailed mechanism by which a STING-mediated signaling relay from PDAC tumor cells to TAMs boost antitumor immunity and contribute to AGP chemotherapy efficacy. Furthermore, STING expression in tumor tissues correlated with improved prognosis, highlighting its potential as a predictive biomarker and promising therapeutic target.

Identification of biomarkers such as Matrix metalloproteinase 1 (MMP1) and the S100A2+ tumor subset, characterization of the basal-like malignant subtype, and interventions like radiofrequency ablation reshaping the PDAC-ME were also discussed. Additionally, the roles of cancer associated fibroblasts and the therapeutic potential inhibitors in combination with signal transducer and activator of transcription 3 blockade and anti-CD47/anti-PD-L1 immunotherapy were reviewed in preventing PDAC resistance.

P3, N=999, Recruiting, Akeso | Not yet recruiting --> Recruiting

Reestablishing ATF4 protein expression rescues the diminished viability due to loss of MondoA expression or activity, providing direct evidence of a link between deregulated MYC and the transcriptional machinery of the ISR. Last, we find that small-molecule inhibition of MondoA is lethal in a subset of PDAC cell lines, including patient-derived organoids, suggesting that the ability to target MYC via chemical inhibition of MondoA transcriptional activity may have broad efficacy.

Furthermore, HAVDI-mediated reprogramming reversed PSC activation within a defined time window, suggesting that both matrix stiffness and mechanical dosing history critically determine reprogramming efficiency. Collectively, this study highlights a novel approach for CAFs reprogramming through mechanical modulation of cadherin signaling, offering new therapeutic potential in PDAC treatment.

The results of this study present important insights regarding risk factors influencing postoperative mortality and offer a potential roadmap for optimising preoperative care and judicious patient selection before pancreatic surgery.

P1/2, N=154, Completed, Akeso | N=250 --> 154 | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: May 2025 --> Nov 2025 | Active, not recruiting --> Completed

P3, N=558, Not yet recruiting, Chipscreen Biosciences, Ltd.

P2, N=160, Recruiting, Akeso | Not yet recruiting --> Recruiting

P1/2, N=84, Not yet recruiting, Anova Innovation Limited